1. A pharmaceutical composition, which comprises tenascin-R (TNR) in solution in a pharmaceutically acceptable carrier; wherein the TNR is in an amount of 0.1 to 1 μg/ml of TNR per ml of solution sufficient to direct migration of neuroblasts within the CNS or within the PNS of a mammal.